Literature DB >> 24977481

Invariant natural killer T (iNKT) cells prevent autoimmunity, but induce pulmonary inflammation in cystic fibrosis.

Nanna Siegmann1, David Worbs, Frauke Effinger, Tobias Bormann, Madlen Gebhardt, Martina Ulrich, Fredrik Wermeling, Eva Müller-Hermelink, Tilo Biedermann, Mike Tighe, Michael J Edwards, Charles Caldwell, Elizabeth Leadbetter, Mikael C I Karlsson, Katrin Anne Becker, Erich Gulbins, Gerd Döring.   

Abstract

BACKGROUND/AIMS: Inflammation is a major and critical component of the lung pathology in the hereditary disease cystic fibrosis. The molecular mechanisms of chronic inflammation in cystic fibrosis require definition.
METHODS: We used several genetic mouse models to test a role of iNKT cells and ceramide in pulmonary inflammation of cystic fibrosis mice. Inflammation was determined by the pulmonary cytokine profil and the abundance of inflammatory cells in the lung.
RESULTS: Here we provide a new concept how inflammation in the lung of individuals with cystic fibrosis is initiated. We show that in cystic fibrosis mice the mutation in the Cftr gene provokes a significant up-regulation of iNKT cells in the lung. Accumulation of iNKT cells serves to control autoimmune disease, which is triggered by a ceramide-mediated induction of cell death in CF organs. Autoimmunity becomes in particular overt in cystic fibrosis mice lacking iNKT cells and although suppression of the autoimmune response by iNKT cells is beneficial, IL-17(+) iNKT cells attract macrophages and neutrophils to CF lungs resulting in chronic inflammation. Genetic deletion of iNKT cells in cystic fibrosis mice prevents inflammation in CF lungs.
CONCLUSION: Our data demonstrate an important function of iNKT cells in the chronic inflammation affecting cystic fibrosis lungs. iNKT cells suppress the auto-immune response induced by ceramide-mediated death of epithelial cells in CF lungs, but also induce a chronic pulmonary inflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24977481     DOI: 10.1159/000362984

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  12 in total

1.  Vitamin D treatment modulates immune activation in cystic fibrosis.

Authors:  T Pincikova; D Paquin-Proulx; J K Sandberg; M Flodström-Tullberg; L Hjelte
Journal:  Clin Exp Immunol       Date:  2017-05-24       Impact factor: 4.330

Review 2.  Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis.

Authors:  Mel Pilar Espaillat; Richard R Kew; Lina M Obeid
Journal:  Adv Biol Regul       Date:  2016-11-14

Review 3.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

Review 4.  Cystic Fibrosis Lung Immunity: The Role of the Macrophage.

Authors:  Emanuela M Bruscia; Tracey L Bonfield
Journal:  J Innate Immun       Date:  2016-06-24       Impact factor: 7.349

Review 5.  Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.

Authors:  Anjali Y Bhagirath; Yanqi Li; Deepti Somayajula; Maryam Dadashi; Sara Badr; Kangmin Duan
Journal:  BMC Pulm Med       Date:  2016-12-05       Impact factor: 3.317

Review 6.  Neutrophil plasticity enables the development of pathological microenvironments: implications for cystic fibrosis airway disease.

Authors:  Camilla Margaroli; Rabindra Tirouvanziam
Journal:  Mol Cell Pediatr       Date:  2016-12-05

Review 7.  CD1: A Singed Cat of the Three Antigen Presentation Systems.

Authors:  Radoslaw Kaczmarek; Mariola Pasciak; Katarzyna Szymczak-Kulus; Marcin Czerwinski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-04-06       Impact factor: 4.291

Review 8.  Airway Inflammation and Host Responses in the Era of CFTR Modulators.

Authors:  Karen Keown; Ryan Brown; Declan F Doherty; Claire Houston; Michael C McKelvey; Shannice Creane; Dermot Linden; Daniel F McAuley; Joseph C Kidney; Sinéad Weldon; Damian G Downey; Clifford C Taggart
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

9.  Knockdown of phosphoinositide-dependent kinase 1 (PDK1) inhibits fibrosis and inflammation in lipopolysaccharide-induced acute lung injury rat model by attenuating NF-κB/p65 pathway activation.

Authors:  Keke Yang; Boqian Li; Jinghua Chen
Journal:  Ann Transl Med       Date:  2021-11

Review 10.  Revisiting the Role of Leukocytes in Cystic Fibrosis.

Authors:  Monica Averna; Paola Melotti; Claudio Sorio
Journal:  Cells       Date:  2021-12-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.